{"id":"https://openalex.org/W129605","doi":null,"title":"Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.","display_name":"Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.","alternate_titles":[],"publication_year":2009,"publication_date":"2009-06-01","ids":{"openalex":"https://openalex.org/W129605","mag":"129605","pmid":"https://pubmed.ncbi.nlm.nih.gov/19528458"},"language":"en","primary_location":{"id":"pmid:19528458","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19528458","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W129605"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075372173","display_name":"James R. Tonra","orcid":"https://orcid.org/0000-0003-3284-7516","observed_orcids":["https://orcid.org/0000-0003-3284-7516"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James R Tonra","raw_affiliation_strings":["ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY10014, U.S.A. James.Tonra@imclone.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY10014, U.S.A. James.Tonra@imclone.com","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002266841","display_name":"Erik Corcoran","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erik Corcoran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083275726","display_name":"Dhanvanthri S. Deevi","orcid":"https://orcid.org/0009-0000-3862-057X","observed_orcids":["https://orcid.org/0009-0000-3862-057X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dhanvanthri S Deevi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049048571","display_name":"Philipp Steiner","orcid":"https://orcid.org/0009-0007-5383-9714","observed_orcids":["https://orcid.org/0009-0007-5383-9714"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philipp Steiner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007758205","display_name":"Jessica A. Kearney","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jessica Kearney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100387046","display_name":"Huiling Li","orcid":"https://orcid.org/0000-0002-1724-2087","observed_orcids":["https://orcid.org/0000-0002-1724-2087"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Huiling Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111662248","display_name":"Dale L. Ludwig","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dale L Ludwig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102120005","display_name":"Zhenping Zhu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhenping Zhu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109922991","display_name":"Larry Witte","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Larry Witte","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046226560","display_name":"David Surguladze","orcid":"https://orcid.org/0009-0006-2488-3751","observed_orcids":["https://orcid.org/0009-0006-2488-3751"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Surguladze","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5074599944","display_name":"Daniel J. Hicklin","orcid":"https://orcid.org/0009-0005-3474-9348","observed_orcids":["https://orcid.org/0009-0005-3474-9348"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel J Hicklin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8581,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.67507012,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"29","issue":"6","first_page":"1999","last_page":"2007"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.026499999687075615,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.007699999958276749,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.8069999814033508},{"id":"https://openalex.org/keywords/igf-1-receptor","display_name":"IGF-1 receptor","score":0.871999979019165},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.9959999918937683},{"id":"https://openalex.org/keywords/combination-targeted-therapy","display_name":"combination targeted therapy","score":0.9200000166893005},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.8970000147819519},{"id":"https://openalex.org/keywords/dc101","display_name":"DC101","score":0.9319999814033508},{"id":"https://openalex.org/keywords/tumor-xenograft-models","display_name":"tumor xenograft models","score":0.7680000066757202},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5550000071525574},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8180000185966492},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":1.0},{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.7260000109672546},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.7160000205039978},{"id":"https://openalex.org/keywords/blood-vessel-density","display_name":"blood vessel density","score":0.8080000281333923},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.6499999761581421}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9358171224594116},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6733643412590027},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6699177622795105},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5446758270263672},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.5407888889312744},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5300098657608032},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.49233734607696533},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4641178250312805},{"id":"https://openalex.org/C14858245","wikidata":"https://www.wikidata.org/wiki/Q18028241","display_name":"Kinase insert domain receptor","level":5,"score":0.4375758767127991},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4374505579471588},{"id":"https://openalex.org/C2777615720","wikidata":"https://www.wikidata.org/wiki/Q11888847","display_name":"Prioritization","level":2,"score":0.4372391104698181},{"id":"https://openalex.org/C26375932","wikidata":"https://www.wikidata.org/wiki/Q118226","display_name":"Growth factor receptor","level":3,"score":0.4259510040283203},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.41808241605758667},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.40667349100112915},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35456162691116333},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35190245509147644},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.24067801237106323},{"id":"https://openalex.org/C146285616","wikidata":"https://www.wikidata.org/wiki/Q7916455","display_name":"Vascular endothelial growth factor A","level":4,"score":0.21693402528762817},{"id":"https://openalex.org/C539667460","wikidata":"https://www.wikidata.org/wiki/Q2414942","display_name":"Management science","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D017526","descriptor_name":"Receptor, IGF Type 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:19528458","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19528458","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},{"id":"mag:129605","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19528458","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1511853133","https://openalex.org/W1570334509","https://openalex.org/W1664817186","https://openalex.org/W1977999028","https://openalex.org/W2003598961","https://openalex.org/W2007400320","https://openalex.org/W2038598054","https://openalex.org/W2077828134","https://openalex.org/W2091874984","https://openalex.org/W2093221289","https://openalex.org/W2098243386","https://openalex.org/W2098531380","https://openalex.org/W2104540972","https://openalex.org/W2106656437","https://openalex.org/W2110860588","https://openalex.org/W2116150263","https://openalex.org/W2123103996","https://openalex.org/W2130461015","https://openalex.org/W2139819066","https://openalex.org/W2147142361","https://openalex.org/W2149278865","https://openalex.org/W2151808807","https://openalex.org/W2152723803","https://openalex.org/W2155305458","https://openalex.org/W2166573361","https://openalex.org/W2168479321","https://openalex.org/W2170655985","https://openalex.org/W2267395365"],"related_works":["https://openalex.org/W2734528602","https://openalex.org/W2098243386","https://openalex.org/W2084910322","https://openalex.org/W876663702","https://openalex.org/W2108042184","https://openalex.org/W2078725062","https://openalex.org/W2354554476","https://openalex.org/W2064022140","https://openalex.org/W2171406886","https://openalex.org/W2079052314"],"abstract_inverted_index":{"BACKGROUND:":[0],"Rational":[1],"strategies":[2,144],"utilizing":[3,145],"anticancer":[4,163],"efficacy":[5],"and":[6,77,92,98,102,122,148,165],"biological":[7],"principles":[8],"are":[9],"needed":[10],"for":[11,20],"the":[12,25,74,106,166,174],"prioritization":[13],"of":[14,79,162,168],"specific":[15],"combination":[16,107],"targeted":[17],"therapy":[18,128,172],"approaches":[19],"clinical":[21],"development,":[22],"from":[23,113,126],"among":[24],"many":[26],"with":[27],"experimental":[28],"support.":[29],"MATERIALS":[30],"AND":[31],"METHODS:":[32],"Antibodies":[33],"targeting":[34],"epidermal":[35],"growth":[36,42,50],"factor":[37,51],"receptor":[38,44,52],"(EGFR)":[39],"(cetuximab),":[40],"insulin-like":[41],"factor-1":[43,88],"(IGF-IR)":[45],"(IMC-A12)":[46],"or":[47,59],"vascular":[48],"endothelial":[49],"2":[53],"(VEGFR2)":[54],"(DC101),":[55],"were":[56,158],"dosed":[57],"alone":[58],"in":[60,62,69,117,129,173],"combination,":[61],"11":[63],"human":[64,90],"tumor":[65,75,84],"xenograft":[66],"models":[67],"established":[68],"mice.":[70],"Efficacy":[71],"readouts":[72],"included":[73],"burden":[76],"incidence":[78],"metastasis,":[80],"as":[81,83],"well":[82],"active":[85],"hypoxia":[86],"inducible":[87],"(HIF-1),":[89],"VEGF":[91],"blood":[93],"vessel":[94],"density.":[95],"RESULTS:":[96],"Cetuximab":[97],"DC101":[99,110,127],"contributed":[100],"potent":[101],"non-overlapping":[103,160],"benefits":[104],"to":[105,155,170],"approach.":[108],"Moreover,":[109],"prevented":[111,124],"escape":[112,125],"IMC-A12":[114],"+":[115,137],"cetuximab":[116,123],"a":[118,130,159],"colorectal":[119],"cancer":[120,132],"model":[121],"pancreatic":[131],"model.":[133],"CONCLUSION:":[134],"Targeting":[135],"VEGFR2":[136,149],"EGFR":[138],"was":[139],"prioritized":[140],"over":[141],"other":[142],"treatment":[143],"EGFR,":[146],"IGF-IR":[147],"antibodies.":[150],"The":[151],"criteria":[152],"that":[153],"proved":[154],"be":[156],"valuable":[157],"spectrum":[161],"activity":[164],"prevention":[167],"resistance":[169],"another":[171],"combination.":[175]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W129605","counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
